· John Crumpler, General Partner and Co-founder of Hatteras Venture Partners
· Christy Shaffer, Ph.D., President and CEO of Inspire Pharmaceuticals
Jeremy Mario, Principal of Private Equity Investments for Mario Family Partners Rick Widin, Vice President, Corporate Affairs & General Counsel for Campbell Alliance.
Williams explains how each of these new appointees will offer invaluable guidance and counsel, “In rebuilding our Board of Directors, we wanted a mix of talent that not only represented the existing foundation of the company, but could also guide its rapid growth and expansion over the coming months and years.”
Williams continues, “We are thrilled to have such a distinguished Board and their commitment to Clinipace speaks volumes for the team we’ve assembled and the hard work of our employees. Along with our management team, each new board member offers something distinct and significant to assist in the growth of our company as we expand to serve our customers. John (Crumpler) has vast software sales and growth company experience and has served on the North Carolina Economic Board; Christy (Shaffer) is a seasoned pharmaceutical executive who has unique expertise in scaling companies, building customer relationships and developing award winning company culture; Jeremy (Mario) serves on several technology and life sciences boards and has extensive experience in the pharmaceutical industry; and Rick (Widin) provides us an incredible depth of experience in not only the legal arena, but in understanding the software, pharmaceutical and biotech industries.”
About Clinipace’s Board of Directors:
Jeff Williams is Chief Executive Officer and Chairman of the Board at Clinipace, and brings over 20 years of pharmaceutical and software experience to Clinipace customers. Over the past four years, Jeff has led Clinipace to significant growth and multiple funding rounds, and continues to guide the company’s growth strategy. As a result, Jeff was named to the PharmaVoice 100, an annual listing of the 100 most influential people in the life sciences industry in 2007.
John Crumpler is co-founder of Hatteras Venture Partners. Formerly a successful software entrepreneur, he was founder and CEO of E-Comm, Inc. John also served on the Economic Development Board of the State of North Carolina. In addition to serving on the board of Clinipace, he is responsible for strategy, administration, and operations of Hatteras Venture Partners.
Christy Shaffer, Ph.D., is the President and CEO of Inspire Pharmaceuticals and a seasoned pharmaceutical executive and Ph.D. scientist with extensive experience in directing complex drug development processes for innovative products. Under Dr. Shaffer’s tenure, Inspire became a publicly traded company in 2000, raising $76 million, and has completed five subsequent equity financings, raising an additional $354 million.
Jeremy Mario serves as Principal, Private Equity Investments for Mario Family Partners and has more than ten years experience in the pharmaceutical and health care fields, ranging from clinical development services to marketing and research. For the past nine years he has managed the private equity portfolio of Mario Family Partners, a diversified asset management company that specializes in early-stage biotech ventures. Jeremy has extensive expertise in helping early stage companies refine business plans and capitalization goals.
Rick Widin is Vice President, Corporate Affairs & General Counsel for Campbell Alliance and has more than 25 years of legal and business experience in corporate and law firm settings, as general counsel or vice president of Business and Legal Affairs for numerous firms, large and small, including General Electric, CSX Corporation, Siebel Systems, and the law firm of White and Case. At Campbell Alliance, Mr. Widin manages all of the company’s legal, risk management and geographic expansion activities.
About Clinipace: Clinipace is a clinical research software company providing a single, integrated data capture and study management platform for post-approval research and registries conducted by biopharmaceutical and medical device companies, Clinical Research Organizations (CROs) and Academic Medical Centers (AMCs). Our platform, called Tempo, is delivered via a web-based, on-demand architecture that streamlines the clinical research process by eliminating the integration headaches associated with multiple platforms, reducing project efforts and costs from startup to conclusion, and empowering project stakeholders to make informed real-time decisions regarding their research. For more information on Clinipace, please visit: www.clinipace.com
Media Contact: David Levin Clinipace, Inc. dlevin@clinipace.com 919.724.4043
